Little Clinic: Fill & Download for Free

Any new institute however well funded, needs some time to matureMost new AIIMS are being hurriedly started on half built campuses with bare minimum recruits most likely freshers with little clinical / academic exposure to run the institute.Even their administration is run from nearby “established” state / central institutes.JIPMER Pondicherry is taking care of AIIMS hyderabad and PGIMER is looking after AIIMS bathinda.My alum, Gandhi Medical College is assigned with academic sessions of AIIMS hyderabad by state / central govt.Although the story is one year, you get the idea.Moral of the story: Do your homework and check ground reality before joining new colleges, doesn't matter if its AIIMS or otherwise.

I am perhaps the one who can answer this question.Research on basic medical sciences spew out huge amount of data, most of which have little clinical relevance. The few with the prospect to become a clinical ‘game-changer’ get dumped and go unnoticed. The ‘lucky’ ones, which manage to get attention are rewarded with academic accolades but more often than not, the storyline fades over time, giving way to the next novelty in research.‘Electron microscopic changes in rat mitochondria rarely change human lives’Translational medicine is translating research for use in bedside.The suffering of the debilitating disease continues to haunt the patient, sitting far away in the hospital ward; waiting for a magic cure; which fails to reach him, on time.This is the first roadblock in translational medicine.The second, perhaps the more important roadblock, is translating the clinical therapy to the benefit of the community at large.The first problem needs to be tackled by focusing research towards clinical problems (rather than research meant for publication in mind) and the second needs educating the physician and health-care professional, to help percolate the benefits to the society at large.This translational medicine is the need of the hour, not only for the new, emerging, healthcare-sensitive India, but also the world at large.

Noopept is a nootropic developed at the Zakusov Institute of Pharmacology or Russian Academy of Medical Sciences by T. A. Gudasheva. It is one of several nootropics developed based on the structure of piracetam. Its advantage over piracetam is that it can be taken at a lower dose.Noopept has a short half-life and is not present in the brain one hour after administration. However, one of its metabolites, cycloprolyglycine (cPG) is increased in the brain one hour after noopept administration, and it is this metabolite that is thought to be responsible for noopept’s longer-term nootropic activities.cPG is also a metabolite of IGF-1 and is under development for rare neurological diseases by Neuren Pharmaceuticals. Noopept is a popular cognitive-enhancing supplement in the nootropic community.Proposed mechanism of actions based on preclinical studies include increasing acetylcholine signaling, increasing the expression of BDNF and NGF, protecting from glutamate toxicity, and increasing inhibitory neurotransmission in the brain.Although noopept is a purported cognitive-enhancing supplement, little clinical evidence supports its use. Evidence in several mouse models suggests that noopept may be neuroprotective, but noopept has a very short half-life and some studies suggest that higher doses may not be beneficial.Also, almost all studies have been conducted in a single laboratory that used non-standard animal models and outcome measures. Some evidence suggests that noopept may have beneficial metabolic effects, but its primary function is as a nootropic.Noopept is associated with some mild side effects based on limited clinical evidence. Described Noopept is not sold over the counter in the United States. It is used clinically in Russia. The only clinical trial with results published in a peer reviewed journal tested a dose of 10mg twice daily.Noopept is associated with some mild side effects based on limited clinical evidence. Noocept is a common nootropic and is used in Russia, but there is little published human clinical evidence on its safety. Since noopept is an unapproved nootropic with little clinical use, drug interactions are not known.